Stockscreener 앱 받기
4.47
3.95%
0.17
시간 외 거래:
4.55
0.08
+1.79%
전일 마감가:
$4.30
열려 있는:
$4.27
하루 거래량:
2.44M
Relative Volume:
0.63
시가총액:
$463.05M
수익:
-
순이익/손실:
$-132.00M
주가수익비율:
-2.3189
EPS:
-1.9276
순현금흐름:
$-96.76M
1주 성능:
-6.29%
1개월 성능:
+43.73%
6개월 성능:
+6.43%
1년 성능:
+73.93%
1일 변동 폭
$4.20
$4.675
1주일 범위
$4.20
$5.01
52주 변동 폭
$1.61
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
명칭
Larimar Therapeutics Inc
전화
844-511-9056
주소
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.47 | 445.44M | 0 | -132.00M | -96.76M | -1.9276 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-29 | 개시 | Truist | Buy |
| 2024-10-16 | 개시 | Oppenheimer | Outperform |
| 2024-10-03 | 개시 | Wedbush | Outperform |
| 2024-10-02 | 개시 | H.C. Wainwright | Buy |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-04-03 | 개시 | Leerink Partners | Outperform |
| 2023-11-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-19 | 개시 | Guggenheim | Buy |
| 2022-02-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 개시 | JMP Securities | Mkt Outperform |
| 2021-02-01 | 개시 | William Blair | Outperform |
모두보기
Larimar Therapeutics Inc 주식(LRMR)의 최신 뉴스
Nomlabofusp push at Larimar Therapeutics (NASDAQ: LRMR) targets 2026 BLA - Stock Titan
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Larimar (LRMR) Poised for Milestone Achievements and Financial S - GuruFocus
Larimar Therapeutics, Inc. has established a clear regulatory approval and commercialization timeline for its core candidate product. - Bitget
Larimar: Q4 Earnings Snapshot - 10TV
Larimar Therapeutics Receives Breakthrough Therapy Designation for Nomlabofusp in Friedreich's Ataxia, Plans BLA Submission for June 2026 - Quiver Quantitative
LRMR: Nomlabofusp advances toward BLA submission with strong cash position and FDA alignment - TradingView
Larimar Therapeutics Q4 net loss widens on higher R&D costs - TradingView
Larimar (NASDAQ: LRMR) secures FDA Breakthrough status and funds runway to 2027 - Stock Titan
BRIEF-Larimar Therapeutics Q4 Net Income USD -62.498 Million - TradingView
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Larimar surges on FDA breakthrough status for lead asset - MSN
IPO Launch: Does Larimar Therapeutics Inc have consistent dividend growth2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Should I invest in Larimar Therapeutics Inc before earningsSwing Trade & Growth Focused Investment Plans - baoquankhu1.vn
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest - MarketBeat
Aug Gainers: How volatile is Larimar Therapeutics Inc stockTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 8%Should You Sell? - MarketBeat
Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail
LRMR: Nomlabofusp shows strong efficacy and regulatory momentum for Friedreich's ataxia, with BLA submission planned for 2026 - TradingView
Larimar Therapeutics posts updated corporate deck outlining nomlabofusp BLA plan, Q2 2026 topline and cash runway - TradingView
Larimar Therapeutics (LRMR) advances nomlabofusp toward 2026 BLA and Phase 3 - Stock Titan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Larimar Therapeutics stock dips after pricing $100M share offering - MSN
Blue Owl Capital Holdings LP Has $18.91 Million Stock Holdings in Larimar Therapeutics, Inc. $LRMR - MarketBeat
ETF Watch: Is Larimar Therapeutics Inc. stock a good choice for value investorsMarket Movers & Verified Swing Trading Watchlists - Naître et grandir
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March - Sahm
Larimar Therapeutics Launches $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Global Legal Chronicle
Larimar Therapeutics price target raised to $12 from $11 at Wedbush - finance.yahoo.com
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp - MyChesCo
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
LRMR Stock Rating Maintained Outperform by Wedbush, Price Target - GuruFocus
Wedbush raises Larimar Therapeutics stock price target to $12 By Investing.com - Investing.com Canada
Wedbush raises Larimar Therapeutics stock price target to $12 - Investing.com
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00 - MarketBeat
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative
LRMR News & Events - Intellectia AI
Larimar Therapeutics: Deerfield entities buy $25m in stock By Investing.com - Investing.com South Africa
Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com Nigeria
James Flynn Acquires 5,000,000 Shares of Larimar Therapeutics (NASDAQ:LRMR) Stock - MarketBeat
Insider Buying: Frank Thomas Acquires Additional Shares of Larim - GuruFocus
Wedbush Adjusts Larimar Therapeutics PT to $12 From $11, Maintains Outperform Rating - marketscreener.com
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance
Larimar Therapeutics Announces Upsized Public Equity Offering - TipRanks
Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView
Larimar Therapeutics prices $100M stock offering at $5 per share - Investing.com Australia
Larimar Therapeutics Prices Upsized $100 Million Public Stock Offering - marketscreener.com
Larimar Therapeutics Inc (LRMR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):